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Abstract
Background: All patients with total hip arthroplasty (THA), especially those with metal-on-metal (MM) THA, are 
exposed to metallic particles and ions, which may cause total or site-specific mortality. We analyzed the causes of total 
and site-specific mortality among a cohort of patients with MM and with metal-on-polyethylene (MP) THA after a long 
follow-up time.
Methods: Standardized mortality ratios (SMR) of total and site-specific causes of death were calculated for 579 patients 
with MM (McKee-Farrar) and 1585 patients with MP (Brunswik, Lubinus) THA for primary osteoarthritis.
Results: Mean follow-up time was 17.9 years for patients with MM and 16.7 years for patients with MP. Overall SMR was 
0.95 for the MM cohort and 0.90 for the MP cohort, as compared to the normal population. Both cohorts showed 
significantly decreased mortality for the first decade postoperatively, equal mortality over the next 10 years, and 
significantly increased mortality after 20 years. Patients with MM THA had higher cancer mortality (SMR 1.01) than 
those with MP THA (SMR 0.66) during the first 20 years postoperatively, but not thereafter.
Conclusion: Both MM and MP prostheses are safe based on total and site-specific mortality of recipients during the 
first 20 postoperative years in comparison with the general population.
Background
Metal-on-metal (MM) total hip arthroplasty (THA) and
especially MM hip resurfacing techniques have recently
regained popularity due to successful mid-term results in
young patients [1-4]. Patients with these prostheses will
be exposed to cobalt and chromium particles and ions for
decades.
MM articulations give rise to particles that are typically
20 to 90 nm in size, with a mean size of approximately 50
nm [5-7]. Because of their small size, MM particles dis-
seminate widely throughout the body, particularly to the
lymph nodes, liver, spleen, and bone marrow [8-12]. The
number of these metallic particles is estimated to be 1000
times greater than that from metal-on-polyethylene (MP)
prostheses [13]. These particles have a large surface area,
and their degradation increases the concentrations of
cobalt and chromium ions in the body fluids. An autopsy
performed more than 25 years after successful implanta-
tion of a McKee-Farrar prosthesis (Howmedica Interna-
tional, Limerick, Ireland) showed elevated levels of cobalt
and chromium in liver, even in the absence of specific
particulate debris in remote sites. This finding suggests
that the metal is stored in the liver as organometallic
complexes or in nanoparticulate form so small that it is
beyond the resolution of electron microscopic analysis
[11].
In an early study [14], nine patients with a McKee-Far-
rar prosthesis had an approximately 3-fold elevation of
chromium and an 11-fold elevation of cobalt in the whole
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Page 2 of 8blood, and a 15-fold elevation in chromium in the urine,
compared with the preoperative values. High serum
metal levels were observed in eight McKee-Farrar
patients after a 20-yearfollow-up, 9-fold higher for chro-
mium and 3-fold higher for cobalt compared with con-
trols [15]. Five patients with Ring prostheses (Downs
Bros, Mitcham, United Kingdom) for an average of 33
years had approximately 5-fold greater serum cobalt lev-
els and 3-fold greater serum chromium levels compared
to patients with a primary or revised MP prostheses or
patients with osteoarthritis (OA) and no implants [16].
Elevated serum chromium and cobalt levels have also
been reported in patients with MP prostheses, but the
concentrations are lower than those in patients with MM
prostheses [17].
Both in vivo and in vitro studies demonstrate chromo-
somal aberrations and DNA damage in association with
debris from cobalt chromium MM and MP prostheses.
An increase in chromatid breaks and gaps are observed in
the bone marrow adjacent to the worn implant [18].
Compared with patients at primary arthroplasty, patients
with mixed types of cobalt chromium prostheses who
underwent revision arthroplasty had a 2.5-fold increase
in the number of peripheral blood lymphocytes in aneu-
ploidy and a 3.5-fold increase in chromosomal transloca-
tions [19]. Debris from worn hip and knee prostheses
damages chromosomes in a dose-dependent manner in
human tissue culture, and is specific to the type of metal.
Cobalt and chromium concentrations correlate with
chromosomal breakage and aneuploidy events, and tita-
nium concentrations correlate with aneuploidy events
[20]. A 2-year prospective study in patients with MM hip
prostheses revealed a significant increase in whole blood
cobalt and chromium concentrations as well as in chro-
mosome aneuploidy and translocations in the peripheral
blood lymphocytes [21].
Therefore, patients with MM and MP hip prostheses
are exposed to cobalt and chromium particles and ions,
which are potentially genotoxic. Long-term exposure to
these metals may affect mortality in these patients. We
analysed the causes of death in patients with MM and MP
total hip articulations over a long follow-up period.
Methods
Basic patient material was identified from the medical
records of two regional orthopaedic hospitals in Finland.
When only patients diagnosed with OA were selected,
the MM arthroplasty group comprised 579 patients who
underwent a McKee-Farrar THA (all cobalt-chromium-
molybdenum) between 1967 and 1973, and the MP series
comprised 1585 patients who had either a Brunswik or
Lubinus (Waldemar Link GmbH & Co., Hamburg, Ger-
many) prosthesis (cobalt-chromium-molybdenum stem)
and who were operated on between 1973 and 1985. Data
for this patient population were reported previously [22].
The proportion of women in the MM group was 66% and
that in the MP group was 61%.
The dates and causes of death during 1971-2005 for the
cohort members were obtained from Statistics Finland by
record linkage using a personal identifier code as the key.
The coverage of the cause-of-death statistics is virtually
complete.
Calculation of person-years at risk started from the
operation and ended at death or closing-date of the study,
December 31, 2005. The number of observed cases for
each cause of death and person-years at follow-up was
stratified by sex, calendar period, 5-year age group, and
follow-up time since the operation. The expected number
of patients to die from each cause was calculated by
applying the number of person-years in each stratum to
the corresponding mortality rate in a similar Finnish pop-
ulation. The calendar periods used were 1971-1974,
1975-1982, 1983-1990, 1991-1998, and 1999-2005; and
the follow-up categories were < 2, 2-9, 10-19, and > 20
years since the operation. The standardized mortality
ratio (SMR) was expressed as the ratio of observed and
expected number of cases. The 95% confidence intervals
(95% CI) were defined based on the assumption that the
number of observed cases followed a Poisson distribu-
tion. The relative mortality risk between patients with
MM or MP THA was calculated as the rate ratio (RR) of
the two SMRs. The 95% confidence limits of the RR were
calculated assuming Poisson distributions.
The list of causes of death included all 53 categories for
which Statistics Finland routinely produces mortality
rates based on the International Classification of Dis-
eases, revisions 8, 9, and 10 [23].
This study was approved by Welfare and Health
Administration of Finland (DNro 639/103/91)
Results
By the end of 2005, 528 (91.1%) of the 579 patients with
an MM prosthesis and 1299 (82.0%) of the 1585 patients
with an MP prosthesis had died. The mean follow-up
times were 17.9 and 16.7 years, respectively (Table 1).
Both groups of patients had a total mortality rate slightly
below the national average. All-cause mortality was sig-
nificantly reduced in both groups during the first postop-
erative decade, similar to that of the general population
during the second postoperative decade, and was signifi-
cantly increased thereafter (Table 2). The RR figures did
not differ significantly between groups in any follow-up
category (Table 2).
Cancer mortality in the MM group was similar to that
in the general population, but the rate was significantly
reduced in the MP group (Table 3, 4). During the first 20
years after THA, the SMR for the MM group (1.01) was
higher than that for the MP group (0.74); RR 1.36 (95% CI
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Page 3 of 81.02-1.79). After 20 years, however, there was no practical
difference between groups (Table 4).
Cardiovascular diseases dominated as the cause of
mortality in both groups; 57% of the MM group and 54%
of the MP group died from cardiovascular disease. All-
over cardiovascular mortality was low during the first
decade postoperatively, equivalent during the next
decade, and slightly increased after 20 years postopera-
tively (Table 5). After 20 years, the SMR was 1.60 (95% CI
1.32-1.92) for women in the MP group compared to 1.45
(95%CI 1.16-1.78) for women in the MM group. These
figures were slightly lower for men; 1.09 for men in the
MP group (95% CI 0.80-1.44) and 1.26 for men in the
MM group (95% CI 0.82-1.84). The increase in mortality
after 20 postoperative years was observed for all forms of
vascular disease, including cerebrovascular diseases for
which the SMRs were 1.56 (95% CI 1.07 - 2.18) in the MM
group and 1.22 (95% CI 0.84 -1.96) in the MP group.
Diabetic mortality was low in the MP group and slightly
decreased in the MM group, but the number of patients
was small (Table 3). There was a slightly increased risk for
dementia or Alzheimer's disease in the MP group (1.20),
which increased with an increase in the time after sur-
gery. After 20 years postoperatively, there were 37
recorded cases with an SMR of 1.54 (95% CI 1.08 - 2.12).
In the MM group, the total risk for this disease was close
to that of the normal population (0.96) (Table 3). After 20
years, 22 patients in the MM group died from this dis-
ease; the SMR was 1.29 (95% CI 0.81 - 1.29).
Mortality from respiratory diseases was low in both
groups (Table 3). The SMR for the MM group remained
low during the first two decades (0.53) and increased
slightly thereafter (0.76). On the other hand, the SMR for
the MP group increased from 0.66 to 1.34 during the
same time period.
Mortality from genitourinary diseases was slightly
decreased in the MM group and slightly increased in the
MP group (Table 3). After 20 years, the SMR for these
diseases in the MM group was 0.77 and 2.13 in the MP
group, but the number of patients was too small to dem-
onstrate statistical significance.
Accidental deaths in both groups were slightly and
equally reduced. In patients over 80 years of age, however,
accidental death due to falling was significantly reduced
in the MP group (SMR 0.45; observed 8, expected 17.72,
95% CI 0.19- 0.88) compared to that in the MM group
(0.87).
Discussion and Conclusions
Total hip arthroplasty dramatically improves a patient's
quality of life, but exposes patients to chronic stress from
cobalt and chromium ions and particles. The MM THA
group included only patients implanted with the first-
generation MM design. The material of the McKee-Far-
rar hip prosthesis was a cast cobalt-chromium-molybde-
num alloy, with a carbon content of approximately 0.2%
that underwent subsequent heat treatment. Its metallur-
gical, tribological, and structural properties are inferior to
Table 1: Number of patients (n) with metal-on-metal or metal-on-polyethylene prostheses stratified by age at operation 
and number of person-years at risk up to the end of 2005 by age at follow-up.
Age (years) Metal-on-metal prosthesis Metal-on-polyethylene prosthesis
n Person-years n Person-years
20 to 29 2 15.5 4 7.1
30 to 39 6 28.7 16 107.0
40 to 49 25 176.2 55 354.7
50 to 59 145 855.6 291 1800.0
60 to 69 278 2836.3 779 6694.5
70 to 79 113 3898.4 419 10848.2
≥ 80 10 2374.3 21 6595.5
Total 579 10185.1 1585 26406.9
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wear rate of the femoral heads ranging from 3.3 to 6.6 μm
and that of cups from 2.1 to 4.9 μm [24]. Due to the high
wear rate, we can assume that if excessive metal ion load-
ing from the McKee-Farrar components did not increase
the risk of mortality within this cohort, such risk would
not be obvious in recipients of MM implants with
improved wear characteristics.
All previous reports of the mortality of THA patients
studied a period of up to only 10 years after surgery.
According to the results of these studies, the 10-year life
expectancy of THA patients is better than that of the gen-
eral population [25,26], which we also observed in the
present study. Patient selection, i.e., the 'healthy patient
effect', probably explains a major part of the better sur-
vival, but the reason for the duration of this effect in dif-
ferent disease groups is not known. In a Swedish Knee
Arthroplasty Register study [27], patients with implanta-
tion of knee prostheses for OA had a reduced overall
mortality during the first 12 postoperative years, which
then increased and became significantly higher than that
of the general population. Cardiovascular, gastrointesti-
nal, and genitourinary diseases were the main causes for
the increased mortality. The authors suspected a link
between the early onset of knee OA and increased mor-
tality. Another study reported reduced SMRs in THA
patients aged 65 years and over in the United Kingdom,
and an increased mortality rate in younger patients; the
preoperative indications, however, were not reported
[28].
Total mortality in the present study did not differ sig-
nificantly between the MM and MP groups across the
postoperative decades. After 20 years postoperatively,
both groups showed significantly increased mortality due
to cardiovascular disease. Altered cardiac function is
reported among hard metal workers. A prolonged left
ventricular relaxation time without clinical consequences
was observed in a series of 203 Finnish cobalt production
workers [29]. The authors concluded that cobalt accumu-
lation in the myocardium could affect its function. An
estimated daily intake of 6 to 8 mg of cobalt chloride or
cobalt sulfate induces cardiomyopathy in heavy beer
drinkers when cobalt is used as a foam stabilising agent in
the beer [30]. Cardiac function, specifically in terms of
cobalt or chromium concentration in the myocardial
cells, in THA patients after long-term use of MM or MP
prostheses has not been studied. Frustaci et al. [31]
observed a large increase in the levels of different trace
elements in the myocardium of 13 patients with idio-
pathic dilated cardiomyopathy, with a 13-fold increase in
the concentration of cobalt and a 4-fold increase in the
concentration of chromium compared to controls. Rela-
tionship of the elevated cobalt and chromium concentra-
tions in the serum of THA patients and cardiomyopathy
requires further studies.
In a large cohort of Finnish OA patients with an MP hip
prosthesis that was not included among patients in the
present study with 153 000 person-years and a mean fol-
low-up of 6.2 years, the SMR for all-site cancer was
reduced to 0.54 [32], and in the present series, after a
mean of 16.2 years, it was still significantly reduced
(0.76). According to a meta-analysis of six Nordic cohorts
operated on for OA, covering 374 000 person-years and a
mean follow-up of 7.6 years, the standardized incidence
Table 2: Observed number of deaths (Obs) (all causes) and standardised mortality ratio (SMR) and rate ratio (RR) among 
patients with metal-on-metal and metal-on-polyethylene total hip prostheses for osteoarthritis by number of 
postoperative years.
Follow-up time, 
completed years
Metal-on-metal prosthesis (n = 579) Metal-on-polyethylene prosthesis (n = 
1585)
Obs SMR 95% CI‡ Obs SMR 95% CI RR 95% CI
0 to 1 16 0.59 0.34-0.96* 35 0.37 0.26-0.51*** 1.61 0.83-2.98
2 through 9 122 0.77 0.64-0.91** 342 0.70 0.63-0.78*** 1.09 0.88-1.35
10 through 19 200 0.94 0.81-1.06 611 0.96 0.89-1.04 0.97 0.82-1.14
20+ 190 1.20 1.04-1.37 * 311 1.38 1.23-1.53*** 0.87 0.72-1.05
Total 528 0.95 0.87-1.02 1299 0.90 0.85-0.95*** 1.05 0.95-1.16
‡ 95% CI, 95% confidence interval
*p < 0.05, **p < 0.01, *** p < 0.001
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Table 3: Observed number of deaths (Obs) and standardised mortality ratio (SMR) among patients with metal-on-metal 
and metal-on-polyethylene total hip prostheses for osteoarthritis in the main disease groups.
Cause of death Metal-on-metal prosthesis (n = 579) Metal-on-polyethylene prosthesis (n = 1585)
Obs SMR 95% CI‡ Obs SMR 95% CI
Cancer 96 0.97 0.79-1.18 206 0.76 0.66-0.86 ***
Cardiovascular 300 0.96 0.86-1.07 702 0.90 0.84-0.97 **
Respiratory 33 0.67 0.46-0.93 * 101 0.78 0.64-0.94 **
Pneumonia 28 0.87 0.58-1.25 79 0.96 0.76-1.20
Alzheimer, 
dementia
28 0.96 0.64-1.38 105 1.20 0.98-1.43
Genitourinary 8 0.90 0.39-1.76 27 1.32 0.87-1.91
Digestive system 18 1.08 0.64-1.71 45 1.07 0.78-1.43
Diabetes 6 0.80 0.29-1.74 7 0.42 0.17-0.86*
Accidents and 
violence
14 0.78 0.42-1.30 38 0.79 0.56-1.07
All causes 528 0.95 0.87-1.02 1299 0.90 0.85-0.95 ***
‡ 95% CI, 95% confidence interval
*p < 0.05, **p < 0.01, *** p < 0.001
Table 4: Observed number of cancer deaths (Obs) and standardised mortality ratio (SMR) and rate ratio (RR) with 95% 
confidence intervals of patients with metal-on-metal and metal-on-polyethylene total hip prostheses stratified by 
number of postoperative years.
Follow-up time, 
completed years
Metal-on-metal prosthesis (n = 579) Metal-on-polyethylene prosthesis (n = 1585)
Obs SMR 95% CI‡ Obs SMR 95% CI RR 95% CI
0 to 1 2 0.35 0.04-1.27 3 0.14 0.03-0.41*** 2.51 0.21 -21.94
2 through 9 29 0.92 0.62-1.32 77 0.78 0.61-0.96* 1.19 0.74 - 1.85
10 through 19 43 1.19 0.86-1.59 89 0.84 0.67-1.02 1.42 0.96 - 2.07
20+ 19 0.84 0.50-1.30 33 0.89 0.61-1.24 0.95 0.51 - 1.71
Total 93 0.97 0.78-1.18 202 0.76 0.66-0.87*** 1.27 0.98 - 1.63
‡ 95% CI, 95% confidence interval
*p < 0.05, **p < 0.01, *** p < 0.001
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0.91-0.95) [33]. In another meta-analysis [34] of patients
with 1.1 million person-years and a mean follow-up time
of 6.2 years operated on for all indications, the SIR was
close to unity, 0.98, 95% CI 0.98-0.99). Goldachre et al.
[35] also reported an SIR of 0.98, 95% CI 0.94-1.01)
among 25 047 THA patients from the United Kingdom
with a mean follow-up of 7.7 years. OA itself is also asso-
ciated with a low comorbidity of cancer. Thomas et al.
[36] reported a low SIR of 0.85 (95% CI 0.81-0.88) for
men and 0.83 (95% CI 0.80-0.86) for women among
patients with all forms of OA in a Scottish cohort. It
seems that first-generation MM or MP prostheses do not
expose patients to an increased risk of cancer. Cobalt and
chromium are essential trace elements and hence a DNA
repair system may exist in the body to rectify DNA dam-
age caused by these ions. Nucleotide excision repair
effectively removes chromium from DNA adducts [37].
In addition, macrophages detoxify the genotoxic and
cytotoxic effects of CoCr particles in vitro [38].
Although cancer genesis may thus be controlled by
these mechanisms, the long-term stress caused by cobalt
and chromium ions may eventually exhaust these func-
tions, which may lead to cellular senescence and apopto-
sis and eventually to a functional failure of the affected
organs. Such development may be reflected by the mor-
tality from other causes.
The number of patients that died from gastrointestinal
and urogenital diseases in the present series was too
small to determine the influence of the implantation on
mortality 20 years postoperatively. The significant
increase in mortality from dementia or Alzheimer disease
20 years after the MP group is noteworthy. Scientific evi-
dence of a relationship between cobalt or chromium
exposure and this disease, however, is lacking.
A limitation of this study is the relatively small number
of patients and therefore chance may explain some of the
results. Both groups showed similar development of all
site mortality, however, over a long follow-up period. In
addition, revisions or bilateral operations were not
reported, but both groups were certainly exposed to
cobalt and chromium debris due to the degradation of
nano-sized metal particles. To our knowledge, revision
was usually performed with the insertion of a new MM or
MP prosthesis.
Over 90% of the patients MM group in the present
series had died. Therefore, their causes of death will not
change. Older cells are less tolerant than younger cells to
cobalt-chromium particles. Nanometer-sized cobalt-
chromium particles induce a greater loss of viability in
older human fibroblast in vitro than in cells from younger
patients [39]. After the 20th post-operative year, both the
MM and MP hip prosthesis group had significantly
increased mortality. Thus, even longer follow-up times
are needed to estimate the risk of death in patients with
modern MM bearings.
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